Aegerion (AEGR +6.6%) continues its uptrend, with the stock close to breaking out of a trading...

|About: Aegerion Pharmaceuticals (AEGR)|By:, SA News Editor

Aegerion (AEGR +6.6%) continues its uptrend, with the stock close to breaking out of a trading range that has persisted since 2011. The stock popped yesterday in reaction to an FDA staff report on its cholesterol drug lomitapide, and has ramped up nearly 35% since Friday in anticipation of its release.